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Cardiorenal syndrome (CRS) refers to a constellation of conditions whereby heart and
kidney diseases are pathophysiologically connected. For clinical purposes, it would be
more appropriate to emphasize the pathophysiological pathways to classify CRS into:
(1) hemodynamic, (2) atherosclerotic, (3) uremic, (4) neurohumoral, (5) anemic–
hematologic, (6) inﬂammatory–oxidative, (7) vitamin D receptor (VDR) and/or FGF23-,
and (8) multifactorial CRS. In recent years, there have been a preponderance data
indicating that vitamin D and VDR play an important role in the combination of renal and
cardiac diseases. This review focuses on some important ﬁndings about VDR activation
and its role in CRS, which exists frequently in chronic kidney disease patients and is a
main cause of morbidity and mortality. Pathophysiological pathways related to sub-
optimal or defective VDR activation may play a role in causing or aggravating CRS. VDR
activation using newer agents including vitamin D mimetics (such as paricalcitol and
maxacalcitol) are promising agents, which may be related to their selectivity in activating
VDR by means of attracting different post-D-complex cofactors. Some, but not all, studies
have conﬁrmed the survival advantages of D-mimetics as compared to non-selective VDR
activators. Higher doses of D-mimetic per unit of parathyroid hormone (paricalcitol to
parathyroid hormone ratio) is associated with greater survival, and the survival
advantages of African American dialysis patients could be explained by higher doses
of paricalcitol (410 mg/week). More studies are needed to verify these data and to
explore additional avenues for CRS management via modulating VDR pathway.
& 2012. The Korean Society of Nephrology. Published by Elsevier. This is an open
access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).rean Society of Nephrology. Published by Elsevier. This is an open access article under the CC BY-NC-
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Combined cardiac and renal dysfunction, referred to as
cardiorenal syndrome (CRS), is common in people with
primary cardiovascular disease and those with kidney
function disorders. It is believed that the incidence and
prevalence of CRS have increased in recent decades, not
only because of increasing occurrence of cardiac or renal
disease but also because of improved longevity of cardiac
and renal patients. Pathophysiologically, heart and kidney
diseases are connected to each other through a number of
pathways, including, but not limited to, hemodynamic
constellations, electrolyte disarrays, immunological disor-
ders, metabolic dysfunctions, neurological derangement,
and inﬂammatory and hormonal factors (Fig. 1).Deﬁnition and classiﬁcation of CRS
Recently, CRS has been more systemically deﬁned and
classiﬁed into ﬁve different types [1]. CRS Types I and II are
described as the primary occurrence of an acute cardiac event
or chronic heart disease, respectively, leading to kidney dis-
orders, whereas in Types III and IV CRS, the primary disease is
acute kidney injury or chronic kidney disease (CKD), respec-
tively, and the cardiovascular disease is a secondary phenom-
enon. Type V is any combination of the above.
Despite the well-intended efforts in providing such novel
deﬁnitions, the usefulness of this classiﬁcation in clinical
approaches and patient management is questionable. Perhaps,
for clinical purposes, it would be more appropriate to empha-
size the pathophysiological pathways, which are the main
etiological role-players and which may have more clinical
utility in patient management. We propose the following
categories (Table 1): ‘‘hemodynamic CRS’’ (when heart failure
leads to renal perfusion comprise and renal functional derange-
ments, or when ﬂuid retention due to primary kidney disease
leads to decompensated heart failure); ‘‘atherosclerotic CRS’’CKD
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Figure 1. Putative pathophysiological connections in cardiorenal syndr
RAAS, renin–angiotensin–aldosterone system; VD/VDR, vitamin D/vitamin(when both atherosclerotic cardiovascular disease and renal
artery disease coexist); ‘‘uremic CRS’’ (when primary kidney
disease leads to myocardial or pericardial dysfunction); ‘‘neu-
rohumoral CRS’’ (when primary electrolyte or acid–base dis-
orders in renal disease or heightened catecholamine release in
cardiac disease or other hormonal derangements lead to
cardiac or renal compromise); ‘‘anemic–hematologic CRS
(when anemia and/or iron deﬁciency lead to cardiac or renal
compromise); ‘‘inﬂammatory CRS’’ (when proinﬂammatory
pathways are activated in either organ and affect the other
organ); and ‘‘vitamin D receptor (VDR)-related CRS’’ (when
VDR activation is suboptimal, leading to a variety of combined
heart and kidney diseases); and ﬁnally in situations where
there are multiple pathophysiological connections, the term
‘‘multifactorial CRS’’ could be used.
In recent years, there have been a preponderance data
indicating that vitamin D and VDR play an important role
in the combination of renal and cardiac diseases. This
review focuses on some important ﬁndings about VDR
activation and its role in CRS.Biological characteristics of vitamin D and VDR
Usually about 50–90% of required vitamin D for the body is
engendered in the skin under the sunshine by converting
dehydro-cholesterol into cholecalciferol (vitamin D3), and the
remainder comes from ingested food in the form of natural or
added cholecalciferol, mostly animal origin, or ergocalciferol
(vitamin D2), mostly plant origin. In the liver, 25-hydoxylase
coverts the latter to 25-OH vitamin D (which is usually
measured in the blood as a screening test), and 1-a-hydox-
ylase in the kidneys coverts the latter to 1,25 di-hydroxy-
cholecalciferol, which is also known as active vitamin D and
which is the most potent activator of VDR (Fig. 2). Although
small amounts of 1-a-hydoxylase also exist in peripheral
(extrarenal) tissues, 490% of vitamin D activation occurs inors 
tors 
 
ctors CVD
ctors 
ome.
D receptor.
Table 1. Suggested Classiﬁcation of CRS According to Pathophysiology and Clinical Utility
Suggested CRS
category
Deﬁnition
Equivalent of
current
deﬁnition
Comments
Hemodynamic
CRS
Heart failure leads to renal perfusion comprise leading to
renal functional derangements, or when ﬂuid retention due to
primary kidney disease leads to decompensated heart failure
All types Can be subclassiﬁed as primary heart or kidney
hemodynamic CRS. Functional subtypes may
include acute, chronic and recurrent
Atherosclerotic
CRS
Both atherosclerotic cardiovascular disease and renal artery
disease coexist
Mostly types
I or II
Uremic CRS Primary kidney disease and uremic toxins leads to myocardial
or pericardial dysfunction (e.g., myocardial dysfunction or
uremic pericarditis)
types III or IV Functional subtypes may include acute, chronic
and recurrent
Neurohumoral
CRS
Primary electrolyte or acid–base disorders (mostly renal
disease) or heightened catecholamine release (mostly cardiac)
or other hormonal derangements lead to cardiac or renal
compromise
All types Functional subtypes may include acute, chronic
and recurrent
Anemic–
hematologic
CRS
Anemia and/or iron deﬁciency lead to cardiac or renal
compromise
Mostly types
III or IV
Functional subtypes may include acute, chronic
and recurrent
Inﬂammatory
CRS
Proinﬂammatory pathways are activated in either organs and
affect the other organ
All types Functional subtypes may include acute, chronic
and recurrent
VDR-related
CRS
VDR activation is suboptimal leading to a variety of combined
heart and kidney diseases such as LVH and proteinuria
All types A direct impact of FGF-23 on myocardium is
possible
Multifactorial
CRS
Situations where there are multiple pathophysiological
connections
All types
CRS¼cardiorenal syndrome; LVH¼ left ventricular hypertrophy; VDR¼vitamin D receptor.
Figure 2. Sources of vitamin D and its metabolism in the body.
Kidney Res Clin Pract 31 (2012) 12–2514the kidneys, hence explaining the main pathophysiological
reason behind inadequate VDR activation in CKD patients.
Most, if not all, biological effects of the hormonal secos-
teroid ligand 1,25-(OH)2-D3 (D-hormone) are mediated by
the VDR, which can also be called D-hormone receptor
(DHR). VDR is a member of the super-family of nuclear
receptors that regulate gene expression. The transcriptional
activity of this receptor is modulated by ligands, such as
steroids, retinoids and other lipid-soluble compounds, and
by nuclear proteins acting as coactivators and co-repressors
[2,3]. The genomic organization of the DHR at locus 12q13.1
shows that the VDR gene itself is large (4100 kb) and has an
extensive promoter region capable of generating multipletissue-speciﬁc transcripts [4]. Activated vitamin D is a highly
ﬂexible molecule, the structure of which can be manipulated
synthetically; hence, many vitamin D analogs have been
synthesized for research or clinical purposes, and some
providing important therapeutic effects with varying
degrees of calcemic activity [5].
Biological effects of VDR
VDR activation inhibits cell differentiation and proliferation
while promoting cell maturation and regulation of apoptosis.
The widespread tissue distribution of VDR suggests that the
D-hormone endocrine system has additional physiological
Figure 3. Interaction between vitamin D regulation and ﬁbroblast growth factor-23.
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limited to, skin [6] and hair follicles [7], immune system
[8,9], cell growth in gastrointestinal tract, prostate and
mammary cancer [10–15], lung and production of surfactant
[16,17], Alzheimer’s disease [18], cardiovascular system, and
even male fertility [19]. Nowadays, it has been revealed that
460 types of cells possess VDRs, 2776 genomic positions are
occupied by the VDR, and 229 genes show signiﬁcant changes
in expression in response to VDR activation. VDR binding sites
are considerably enriched near autoimmune and cancer-
associated genes identiﬁed from genome-wide association
studies [20]. It has been demonstrated that many tissues not
only express the VDR but also may possess small amounts of
1-a-hydroxylase, and are therefore, capable of the production
of paracrine 1,25-(OH)2-D3, which may act locally. However,
VDR multiple polymorphisms have also been described
in association with different malignant and nonmalignant
diseases.
An important function of the VDR complex is to
regulate the level of renal 1,25-(OH)2-D3 biosynthesis.
1,25-(OH)2-D3 appears to affect a short feedback loop to
repress 1-a-hydroxylase [21], and is also a potent sup-
pressor of the synthesis and secretion of parathyroid
hormone (PTH), the primary hormone stimulating 1-a-
hydroxylase. The mechanism by which 1,25(OH)2-D3
reduces PTH production involves a VDR-mediated silen-
cing of PTH gene transcription [22–25].
Similar constellations of feedbacks and modulations
also exists for ﬁbroblast growth factor (FGF)-23, which
may be even more involved with phosphorus regulation
including its renal excretion (Fig. 3).
Circulating vitamin D
Deﬁnition and measurement methods
Measuring serum level of 25-(OH) vitamin D concen-
tration is the most commonly used assessment of vitamin
D status. Acceptable levels are not known exactly but thegeneral recommendations are between 30 and 60 ng/mL
(70–150 nmol/L). Vitamin D insufﬁciency is deﬁned when
the levels are between 20 ng/mL and 29 ng/mL and at
levels of r20 ng/mL (or o15 ng/mL according to some
guidelines such as Kidney Disease Outcomes Quality
Initiative; KDOQI), the patient is considered to be vitamin
D deﬁcient. It is important to note that besides the
deﬁnition of vitamin D insufﬁciency and deﬁciency varia-
tions, methods of 25-(OH)-D assessment vary between
studies. Also, it is important to know that 25-(OH)-D has
higher afﬁnity for vitamin D binding protein (VDBP) than
1,25-(OH)2-D3; whereas, 1,25(OH)2-D3 has the highest
afﬁnity for VDR when compared to 25-(OH)-D, which
may have no meaningful afﬁnity to VDR at physiological
concentrations. Hence, 25-(OH)-D is much less potent
than 1,25-(OH)2-D3 [26], suggesting that without ade-
quate 1-a-hydroxylation in the kidneys, as is the case in
most terminal CKD patients, examining the level of 25-
(OH)-D may be of little signiﬁcance for optimal health and
well-being of these patients. It is also important to note
that methods for measuring 25(OH)-D levels vary widely.
Especially at lower vitamin D levels, some commonly used
assays show up to 80% differences [27]. These assays
include competitive protein-binding assay, radioimmu-
noassay, enzyme immunoassay, chemiluminescence
immunoassays, high-performance liquid chromatogra-
phy, and liquid chromatography–mass spectrometry; and
each of them have a number of advantages and disadvan-
tages beyond the scope of this review. There is signiﬁcant
interassay and interlaboratory variability in measure-
ments even at usual levels [28]. Furthermore, some assays
measure both D2 and D3, whereas some measure only D3
or differentially and each separately. Therefore, comparing
vitamin D status between studies is not reliable unless the
exact same deﬁnition and assay and type of D (D2 vs. D3)
are clariﬁed adequately. The assays should be appropri-
ately cross-calibrated in clinical studies and patient man-
agement [29]. Finally, most of these studies are in non-
CKD patients, and there is virtually no study to examine
Kidney Res Clin Pract 31 (2012) 12–2516the reliability of these assays in the uremic milieu of CKD
patients.
Prevalence and risk factors of vitamin D deﬁciency
Low-level vitamin D status is a common problem in the
general population. Levels of 25-(OH)-D below 30 ng/mL
are prevalent in every region studied, whereas very low
levels below 10 ng/mL are also common in regions such as
South Asia and the Middle East. Factors that are signiﬁ-
cantly associated with lower vitamin D levels include
older age, female sex, higher latitude, winter season,
darker skin pigmentation, less sunlight exposure, dietary
habits, and absence of vitamin D fortiﬁcation [29].
Vitamin D deﬁciency is a common problem among CKD
patients. In one prospective study of 140 CKD patients, it
has been revealed that about 42% and 34% of patients
suffered from vitamin D deﬁciency and insufﬁciency,
respectively [30]. In a recent cross-sectional analysis of
1026 adult patients across all stages of non-dialysis-
dependent CKD, the prevalence of 25-(OH)-D deﬁciency
was associated inversely with glomerular ﬁltration rate
(GFR), ranging from 28% and 51% for GFR Z60 mL/min/
1.73 m2 and o15 mL/min/1.73 m2, respectively. The vita-
min D deﬁciency was higher in patients of African origin,
those with obesity, diabetes, hypertension, macroalbumi-
nuria and hypoalbuminemia, and also during winter [31].Role of vitamin D in CKD
Effect of low vitamin D level on mortality
A recent meta-analysis has revealed that the relative
risk of mortality per 10-ng/mL (25-nmol/L) increase in
25-(OH)-D level was 0.86 [95% conﬁdence interval (CI):
0.82–0.91], suggesting 14% greater survival beneﬁt across
each 10-ng/mL higher level [32]. In patients with very low
levels of vitamin D (o16.7 ng/mL) mortality rate was
signiﬁcantly higher. Multivariate adjustments (including
for age, sex, diabetes, arterial pressure, CKD stage, phos-
phorus, albumin, hemoglobin, aortic calciﬁcation score,
and pulse wave velocity) conﬁrmed 25-(OH)-D level as an
independent predictor of all-cause mortality. As a resultCKD
Nutritional deficiency   Megalin receptors Renal mass 
GFR Loss of 2
PTH Dec
Vitamin D3 uptake 
Vitamin D3    
1-24-hydroxylase activity  
Figure 4. Putative mechanisms involve in the decreased levels of 1,25(O
disease patients.
CKD, chronic kidney disease; FGF-23, ﬁbroblast growth factor-23, GFR, gloof decreased level of vitamin D, hypoparathyroidism
occurs. The combination of persistently high PTH and
low 1,25-(OH)2-D3 is associated with bone loss, cardio-
vascular disease, immune suppression and increased mor-
tality in patients with end-stage kidney failure [30]. CKD
stage 5 patient are at a higher risk for cardiovascular
disease and stroke as leading causes of mortality, which is
about 10–20-fold higher than the age- and sex-matched
general population [33].Mechanisms of vitamin D deﬁciency in CKD
Hydroxylation by cytochrome P450 27B1 (CYP-27B1) is
the rate-limiting step in the activation of vitamin D and
production of 1,25-(OH)2-D3 [34]. Another hydroxylase,
CYP24A1, represents the ﬁrst step in the inactivation of
1,25-(OH)2-D3 [6,25]. Generally, 25-OHD-1a-hydroxylase
(CYP27B1), which is expressed as the highest concentration
in the kidney, is positively regulated by calcium, PTH,
calcitonin, growth hormone, and insulin-like growth fac-
tor-I, and negatively regulated by phosphate, FGF-23, and
1,25-(OH)2-D3 itself [35]. There seem to be several mechan-
isms involved in the decreased levels of 1,25-(OH)2-D3 that
occur in the course of kidney disease (Fig. 4).1.5(OH)
rease 
H)2-D
meruMaintaining circulating level of 25-(OH)-D is an
important key factor for nonrenal calcitriol synthesis.
In CKD, progressive loss of this substrate, besides the
lower capacity for conversion of it to circulating
calcitriol, has been observed [36].2. A decrease in renal mass (independent of renal func-
tion) limits substantially the quantities of 1-a-hydro-
xylase that are available for production of active
vitamin D metabolites.3. GFR reduction limits substrate delivery to the 1-a-
hydroxylase sites, which further decreases the ability
of the kidney to synthesis 1,25-(OH)2-D3.4. The progressive decline in kidney function (independent
of renal mass) is associated with loss of renal 1-a-
hydroxylase (CYP27B1), resulting in gradual decline in
circulating 25-hydroxyvitamin D and 1,25-(OH)2-D3.5. Decrease in uptake of vitamin D3 bound to vitamin D
binding protein by megalin receptors in the proximalD 
Loss of 1-alfa-hydroxylase 
  Phosphate retention 
1-alfa-hydroxylase activity  
FGF-23  
1-alfa-hydroxylase expression 
3 in the course of kidney disease progression in chronic kidney
lar ﬁltration rate; PTH, parathyroid hormone.
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deﬁciency presenting in CKD [37,38].6. Another factor that may be involved in decreased
vitamin D in CKD is phosphorus retention that causes
a decrease in activity of 1-a-hydroxylase (Fig. 3) [39].7. Northern blot analysis has revealed that FGF-23
decreases 1-alpha-hydroxylase expression and
increases 24-hydoxylase expression, starting as early
as 1 h after administration. In CKD subjects, FGF-23
levels rise in parallel with declining renal function
long before a signiﬁcant increase in serum phosphorus
concentration can be detected [40].8. An additional factor that may be involved is the
potential for N-terminally truncated PTH fragments
or C-terminal PTH fragments to decrease activity of
1-a-hydroxylase [41].9. Few foods contain vitamin D, therefore, humans
including CKD patients depend on sun exposure to
satisfy their requirements for vitamin D. High inci-
dence of nutritional vitamin D insufﬁciency or deﬁ-
ciency, in parallel with uremic malnutrition (including
anorexia and protein-energy wasting), and sun expo-
sure deprivation could be additional important factors
for low levels of vitamin D in CKD patients.10. Serum levels of 25-(OH)-D is the main determinant of
1,25-(OH)2-D3 tissue levels in various organs. Further-
more, 24-hydroxylation of 25-(OH)-D or 1,25-(OH)2-
D3 is considered the main degradation process and
produces ineffective vitamin D metabolites [24,25-
(OH)2-D or 1,24,25-(OH)3-D], which are converted to
water-soluble inactive calcitroic acid [39]. The decline
in circulating 1,25-(OH)2-D3 in CKD might be a con-
sequence of increased inactivation (24-hydroxylation)
rather than of reduced production (1a-hydroxylation)
of 1,25-(OH)2-D3 [42].Risk factors for vitamin D deﬁciency in CKD
Aging, diabetes and obesity are generally the major risk
factors for hypovitaminosis D in the general population as
well as in non-dialysis-dependent CKD patients [43].
Additionally, in patients with CKD stage 5 undergoing
hemodialysis, lower values of 25-(OH)-D seem to be
associated with female sex, increased body mass index,
and worse functional class of CKD [44].Vitamin D and CRS
Cardiovascular mortality is the leading cause of death
in the entire spectrum of CKD, including dialysis and
transplanted patients, with mortality 10–30 times higher
than in the general population, despite stratiﬁcation for
sex, race, and presence of diabetes. Similarly, cardiovas-
cular mortality is 2–5 times higher than in the general
population in patients with a functioning renal transplant
[33]. However, cross-sectional studies have demonstrated
that the Framingham risk equation is insufﬁcient to
capture the extent of cardiovascular disease in CKD sub-
jects, implying the presence of additional risk factors [45].Expression of the VDR and vitamin D metabolizing
enzymes in the myocardium and endothelial system
suggests a role for vitamin D in the cardiovascular system.
Many precursor states of heart failure, such as hyperten-
sion, atherosclerosis, and diabetes are more prevalent in
subjects with low vitamin D levels. Furthermore, vitamin
D deﬁciency leads to secondary hyperparathyroidism and
both primary and secondary hyperparathyroidism are
associated with cardiovascular pathologies [46]. In CKD,
vitamin D plays a prominent role in the progression of
heart failure, hypertension, myocardial hypertrophy and
an increased prevalence of cardiovascular risk factors and
related morbidity and mortality (see below) [47–49].
Role of PTH in CRS
An increased risk of cardiovascular diseases in patients
with primary hyperparathyroidism without CKD has been
reported [50]. In the line with this, hypertension, impaired
glucose tolerance and chronic inﬂammation have been
associated with primary hyperparathyroidism [51–54]. One
study has suggested the possible role of PTH in the differ-
ence in adipose tissue gene expression. Many of those most
upregulated genes have been implicated in inﬂammatory
diseases, whereas many of the downregulated genes play
roles in lipid and carbohydrate metabolism that suggest that
downregulation of metabolic genes in primary hyperpar-
athyroidism patients may confer, or at least reﬂect, meta-
bolic dysregulation and may be contributed in
cardiovascular disease [55]. Elevated PTH has been shown
to play a role in abnormal vasodilatation [56]. In patients
with primary hyperparathyroidism, parathyroidectomy sig-
niﬁcantly improves endothelial vasodilatory function [57]. In
one recently published article, highly signiﬁcant differen-
tial cardiovascular disease prevalence/incidence rates
for most cardiovascular risk factors, disease, diagnoses,
and mortality were noted for PTH475 pg/mL (by 1.25–
3-fold). PTH is correlated weakly with 25-(OH)-D and
moderately with GFR. In this study, 25(OH)-D level,
standard risk factors, and renal dysfunction variably
attenuated PTH risk associations, but the risk still
persisted after full multivariable adjustment [46].
Renin–angiotensin system and blood pressure
Associations of minerals and bone and blood pressure
have been the focus of many studies. In most of these
studies, there has been no or little difference in mean
blood pressure (BP) between the group of patients who
took calcium supplements and the control (placebo)
group. Heterogeneity between trials could not be
explained by dose of calcium or baseline BP [58–60].
However, a recent study in rats has revealed signiﬁcant
elevation in BP and heart rate in association with low
vitamin D level [61]. Also, a relationship between
cutaneous vitamin D photosynthesis and BP has been
conﬁrmed experimentally by Krause et al. [62] who have
found UV-B irradiation not only signiﬁcantly increased 25-
(OH)-D concentrations but also lowered BP; an effect not
seen with exposure to UV-A radiation.
Kidney Res Clin Pract 31 (2012) 12–2518Some clinical studies have suggested an inverse relation-
ship between the plasma 1,25-(OH)2-D3 concentrations and
BP and/or plasma renin activity in both normotensive men
and patients with essential hypertension [63–67]. However,
at least one study has shown no difference in systolic and
mean BP after 6 months, and even a decrease in mean
systolic pressure after 9 months in VDR knockout (VDR-KO)
mice. In this study, heart weight/body weight ratio was 41%
greater in the VDR-KO mice than wild-type (WT) mice
(po0.003). Interestingly, other VDR-KO mouse tissues did
not display hypertrophy. Trichrome staining of heart tissue
showed marked increase in ﬁbrotic lesions in the VDR-KO
mice. Analysis of plasma showed elevated renin activity and
angiotensin II and aldosterone levels in VDR-KO compared
with WT mice [68].
Role of nitric oxide pathway in VDR–CRS link
Calcium is required for the activity of nitric oxide (NO)
synthase, and thus, increasing extracellular or intracellular
calcium concentrations may stimulate NO production. An
increase in serum calcium may also alter the intracellular
calcium level, leading to opening of endothelial calcium-
sensitive potassium channels, and vessel relaxation. Aortic
endothelial NO synthase expression and urinary NOx
excretion appear to be reduced in hypocalcemic VDR-KO
mice but not in normocalcemic VDR-KO mice [69].
Whether NO pathways are involved in the VDR–CRS link
remains to be determined in additional studies.
Thrombogenicity and platelet pathway
It seems that platelet aggregatory threshold in association
with VDR activity is partly related to calcium level. In one
study, platelet aggregatory index values in hypocalcemic
VDR-KO mice were increased markedly compared with
those in WT mice (po0.01). In contrast, platelet aggregatory
threshold index values in normocalcemic VDR-KOmice were
signiﬁcantly lower than those in WT mice (po0.05). These
results demonstrate that hypocalcemia is responsible for the
suppression of platelet aggregation in VDR-KO mice fed a
regular diet, and that VDR itself has a suppressive effect on
platelet aggregability [70]. The gene expression of antith-
rombin in the liver and that of thrombomodulin in the aorta,
liver and kidney was downregulated in hypo- and normo-
calcemic VDR-KO mice [65]. However, VDR-KO mice man-
ifest normal prothrombin time and activated partial
thromboplastin time as in WT mice. These results demon-
strate that the loss of VDR function does not lead to impaired
blood coagulation and is consistent with the fact that VDR-
KO mice do not show a bleeding tendency [66].
Lipid metabolism and VDR
The exact role of VDR in lipid metabolism is not clear. In
one study, uncoupling protein-1, which mediates dissociation
of cellular respiration from energy production, was elevated
by 425-fold in VDR-KO mouse white adipose tissue. Con-
sistent with this elevation in uncoupling protein-1, VDR-KO
mice were resistant to high-fat-diet-induced weight gain [71].In contrast, several cross-sectional studies have
reported a strong inverse association between 25-OH-D
level and prevalence of obesity (body mass index, waist
circumference, waist: hip ratio, total body fat percentage
and total body fat mass); a direct association between PTH
and obesity has also been described [72,73]. In another
cross-sectional study in overweight adult African Amer-
icans, depressed 25-OH-D and elevated PTH levels were
both linked to body composition, fat distribution and
anthropometric measures [74].
Coronary artery calciﬁcation
Coronary artery calciﬁcation may be present even in the
early phases of CKD; the prevalence is greater in patients
with renal dysfunction than in controls, but less than that in
dialysis patients [75]. Up to 80% of all dialysis patients have
vascular calciﬁcation [76]. This means at least 2–5-fold more
frequent coronary artery calciﬁcation than age-matched
individuals with angiographically proven coronary artery
disease [77]. Serum concentrations of calcium, phosphorus,
PTH, and inﬂammatory markers may or may not predict the
risk of pre-existing or progressive coronary artery calciﬁca-
tion [75]. Although serum alkaline phosphatase 4120 U/L
does so [78]. In another study on 81 patients on hemodia-
lysis, older age and higher PTH and serum calcium were
associated with higher coronary calcium score, which is a
predictor of higher mortality in dialysis patients [79]. In a
study by Mizobucchi et al., higher risk of vascular calciﬁca-
tion in uremic rats was seen upon exposure to calcitriol or
doxercalciferol (a 1-a-OH-vitamin-D2) but not with parical-
citol (19-nor-dihydroxy-D2).
African American race and vitamin D link
Vitamin D deﬁciency is more common among African
Americans, whose dark skin makes vitamin D photosynth-
esis inefﬁcient. Most Africans and others with deep skin
pigmentation live at or near the equator. Compared with
those living at more northern or southern latitudes, native
Africans and other people of color living near the equator
have a lower prevalence of hypertension. It has been
demonstrated that for each 101 north or south of the
equator, BP increases by 2.5 mmHg and hypertension
prevalence by 2.5%, which may indicate the link with the
VDR activation pathway [80,81]. Moreover, about half of
the BP difference noted between African Americans and
European Americans could be explained by vitamin D
deﬁciency. Although these statistical associations may
suggest associations, they do not prove causality.
Vitamin D and diabetes
In a study of disease-free adults in the National Health
and Nutrition Examination Survey (NHANES) 2001–2006,
mean vitamin D concentration was signiﬁcantly lower in
adults with pre-diabetic status or undiagnosed diabetes
compared with those with normoglycemia (p¼0.004 and
p¼0.0002, respectively). Mean serum vitamin D concen-
trations in those with desirable BP (o120/80 mmHg),
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or diastolic BP 80–89 mmHg), and untreated hypertension
(BPZ140/90 mmHg) were 67.9 nmol/L, 61.5 nmol/L and
62.4 nmol/L, respectively. Compared with those with
desirable BP, adults with pre-hypertensive BP ranges had
signiﬁcantly lower mean vitamin D concentration
(po0.001) [82]. In another prospective study, those who
developed diabetes had lower serum 25-OH-D (mean:
58 nmol/L vs. 65 nmol/L; po0.001) and calcium intake
(mean: 881 mg/day vs. 923 mg/day; p¼0.03) compared
with those who remained free of diabetes. Each 25-nmol/L
increment in serum 25 (OH) D was associated with a
24% reduced risk of diabetes (odds ratio: 0.76; 95% CI:
0.63–0.92) after adjusting for age, waist circumference,
ethnicity, season, latitude, smoking, physical activity, family
history of diabetes, dietary magnesium, hypertension, serum
triglycerides, and fasting plasma glucose. Dietary calcium
intake was not associated with reduced diabetes risk [83].
Animal and human studies have indicated that vitamin D
can have a direct (via activation of the VDR on pancreatic
b-cells and insulin-sensitive organs) and indirect (via reg-
ulation of calcium homeostasis) positive effect on insulin
secretion and sensitivity [84,85].
Heart failure
Vitamin D3 deﬁciency and insufﬁciency are associated
with the etiology and pathogenesis of congestive heart
failure [86]. Ablation of the VDR in mice and vitamin D
deﬁciency in rats leads to cardiac hypertrophy and ﬁbrosis
[87]. An increase in c-myc protein levels observed in the
hearts of the vitamin D3-deﬁcient rats suggests that 1,25-
(OH)2 D regulates c-myc expression [88]. The proto-
oncogene c-Myc (Myc) has been shown to be increased
in many different types of heart disease, including hyper-
trophic cardiomyopathy, before any signs of the disease
are present; c-Myc (Myc) is highly expressed in fetal and
proliferating cardiomyocytes. However, soon after birth,
cardiomyocytes cease to divide, corresponding with the
downregulation of Myc [89]. c-Myc proto-oncogene is
induced in the ventricular myocardium within 1 hour
after imposition of pressure overload [90]. Myc also plays
a role in the maintenance of mitochondrial function [91].
A 2-week induction of Myc resulted in an approximately
twofold increase in gravimetric cardiac mass normalized
to body weight compared with Myc-OFF mice, and the
expression of both atrial and brain natriuretic peptides
was signiﬁcantly increased after 1 week induction and
then decreased after 2 weeks induction [92]. Myc over-
expression for 2 weeks produced decompensated hyper-
trophic cardiomyopathy characterized by impaired
systolic and diastolic function.
Stroke, sudden cardiac death and myocardial infarction
25-(OH)-D was measured in 1108 diabetic hemodialy-
sis patients, who participated in the German Diabetes
Dialysis Study (4D) and were followed for a median of
4 years; patients with severe vitamin D deﬁciency tended
to have a 2.8-fold nonsigniﬁcant increased risk of strokecompared with those with normal levels [adjusted hazard
ratio (HR): 2.83, 95% CI: 0.82–9.80], but the risk of fatal
and nonfatal myocardial infarction did not increase at
lower levels of 25-(OH)-D. Sudden cardiac death was
threefold higher in patients with severe vitamin D deﬁ-
ciency as compared with those with sufﬁcient 25(OH)-D
levels (HR: 2.99, 95% CI: 1.39–6.40). This association was
virtually unchanged after controlling for potential con-
founders and seasonal variation of 25-(OH)-D (HR: 2.95,
95% CI: 1.35–6.46) [93].Management of CRS
Vitamin D supplement therapy
Some guidelines suggest correcting reduced 25-(OH)-D
concentrations in CKD patients with an estimated GFRo
60 mL/min/1.73 m2. Calcitriol and its analogs including vita-
min D mimetics that activate VDR directly are commonly
used to manage hyperparathyroidism secondary to CKD
[94]. It has been shown that vitamin D3 supplementation
reduces BP in patients with essential hypertension [95,96].
Similarly, in hyperparathyroidism, plasma renin activity and
angiotensin II levels are different [97,98]. In one study,
subjects who received calcitriol experienced a 9% decrease
in mean systolic BP compared to that in the matched
placebo group. However, after 1 week, BP returned to
pretreatment levels, suggesting at least an effective short-
term intervention for reducing BP [99]. In a recent study, 15
out of 94 (16%) infants with severe left ventricular dysfunc-
tion had severe hypocalcemia due to vitamin D deﬁciency;
vitamin D levels were at lower limit of normal, but deﬁnitely
low for that degree of hypocalcemia. All these infants except
for one responded dramatically to therapeutic doses of
vitamin D and calcium [100].
Vitamin D analogs and D-mimetics
Different types of VDR activators are shown in Fig. 5. In
1998, paricalcitol (19-nor-1,25-OH2-D2) was approved for
the treatment of hyperparathyroidism in chronic renal fail-
ure. Reductions in PTH occurred more rapidly and with least
calcemic effects in subjects administered with paricalcitol
compared with calcitriol, whereas the percentage of subjects
experiencing severe hyperphosphatemia (serum phosphor-
us48.0 mg/dL) was greater in those administered calcitriol
compared with paricalcitol [101]. Several clinical studies
have shown that VDR activation therapy was successful in
increasing survival in CKD patients. In this regard, paricalci-
tol revealed more beneﬁts than calcitriol, and both of them
were more effective than no VDR activation therapy; these
results seemed to be independent of PTH and calcium levels
[102–104]. Other VDR-activating compounds have been
invented in an attempt to ﬁnd the most appropriate treat-
ment, such as doxercalciferol and alfacalcidol. In a study on
37 dialysis patients, paricalcitol was successful at controlling
secondary hyperparathyroidism in patients resistant to cal-
citriol therapy, with minimal impact on calcium and phos-
phorus homeostasis [105]. In another double blind
randomized study on 88 patients with secondary
Figure 5. Different types of active vitamin D analogs including non-selective vitamin D receptor activators and vitamin D mimetics.
CKD, chronic kidney disease; sHPT, secondary hyperparathyroidism; VDR, vitamin D receptor; VDRA, VDR agonist.
Kidney Res Clin Pract 31 (2012) 12–2520hyperparathyroidism, 3 weeks administration of paricalcitol
caused a signiﬁcant decrease in PTH, with a mean 30%
reduction [106]. In another study, compared to the uremic
control group, paricalcitol treatment in uremic patients
greatly reduced PTH levels (po0.01) and partially inhibited
the development of left ventricular hypertrophy. Four weeks
treatment with paricalcitol signiﬁcantly prevented
decreased VDR expression in myocardial cells. Also, left
ventricular ﬁbrosis and vessel thickness, which are major
causes of cardiomyopathy in uremic patients, signiﬁcantly
decreased [107]. The endothelial-dependent relaxation was
enhanced in nephrectomized rats treated with paricalcitol
for 2 weeks, whereas it did not affect BP or heart rate.
PTH suppression alone did not improve endothelial
function because cinacalcet, a calcimimetic, suppressed
PTH without affecting endothelial-dependent vasorelaxation
[103,108,109]. Hence, the effect of paricalcitol on improv-
ing endothelial function and left ventricular hypertrophy
appears to be independent of BP control [110,111]. In
another study, in spontaneously hypertensive rats with
impaired endothelial function, oral cholecalciferol (vita-
min D3) treatment signiﬁcantly improved the endothe-
lium-dependent vascular relaxation and hyperpolarization
induced by acetylcholine [112]. A study by Freundlich
et al. [113] has reported that plasma creatinine level,
elevated in all groups with renal ablation, started to
decline after 2 weeks of paricalcitol treatment.
Different vitamin D analogs have been compared in their
effects and side effects by several studies. A randomized
control trial has compared outcome of 16 weeks treatment
with paricalcitol versus ergocalciferol. In 80 patients with
CKD, low 25-OH-D3 level and secondary hyperparathyroid-
ism, for lowering PTH level, paricalcitol was more effective
than ergocalciferol, and for increasing serum 25-(OH)-D
levels, ergocalciferol was more effective [114]. In another
study in NTX Cyp27b1-null mice, which completely lack
endogenous calcitriol, effects of oral doxercalciferol (1-a-
OH-D2) and paricalcitol have been examined. Doxercalciferolat 100 pg/g or 300 pg/g normalized serum calcium and PTH
levels. Paricalcitol at 300 pg/g or 1000 pg/g normalized
serum calcium, but less so with PTH levels. Osteomalacia
was corrected by 100 pg/g doxercalciferol or 1000 pg/g
paricalcitol. The highest dose of doxercalciferol, but not of
paricalcitol, signiﬁcantly reduced osteitis ﬁbrosa [115]. Sev-
eral limitations of the study were noticeable, making the
accuracy of these results somewhat questionable. In a multi-
center randomized clinical trial in hemodialysis patients,
effects of intravenous alfacalcidol (D3) and paricalcitol (D2)
were compared for 16 weeks. Paricalcitol was more efﬁcient
at correcting low than high baseline PTH levels, whereas
alfacalcidol was equally effective at all levels. There were no
differences in the incidence of hypercalcemia and hyperpho-
sphatemia [116]. This study should be qualiﬁed for its small
sample size and several other limitations. In general, VDR
activation mitigates the impact of uremia on endothelial
function in uremic animal models [117].
Other possibilities for future management of CRS
The administration of exogenous pyrophosphate, a potent
inhibitor of vascular calciﬁcation, usually deﬁcient in CKD,
can inhibit uremic vascular calciﬁcation without producing
adverse effects on bone [118]. Inhibition of proto-oncogene
Myc is becoming an attractive paradigm for prevention and
treatment of cardiomyopathy and heart failure. The nuclear
hormone 1,25-(OH)2-D3 downregulates Myc expression, but
the exact mechanism is still elusive [119]. Bone morphoge-
netic protein-7 may inhibit the progression of vascular
calciﬁcation induced by conditions such as high levels of
vitamin D or phosphate [120].
Epilogue
CRS exists frequently in CKD patients and is a main
cause of morbidity and mortality. Pathophysiological
pathways related to suboptimal or defective VDR
S Darabian et al / Cardiorenal syndrome and vitamin D receptor activation in chronic kidney disease 21activation may play a role in causing or aggravating CRS.
VDR activation using newer agents including vitamin D
mimetics (such as paricalcitol and maxacalcitol) are pro-
mising agents, which may be related to their selectivity in
activating VDR by means of attracting different post-D-
complex cofactors. Some [103], but not all [121], studies
have conﬁrmed the survival advantages of D-mimetics as
compared to nonselective VDR activators. Indeed, higher
doses of D-mimetic per unit of PTH (paricalcitol to PTH
ratio) is associated with greater survival [122], and the
survival advantages of African American dialysis patients
could be explained by higher doses of paricalcitol
(410 mg/week). More studies are needed to verify these
data and to explore additional avenues for CRS manage-
ment via modulating VDR pathway.Conﬂict of interest
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